Spots Global Cancer Trial Database for Expanded Access to Veliparib

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Expanded Access to Veliparib

Official Title: Expanded Access to Veliparib

Study ID: NCT03123211

Conditions

Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound

Triple Negative Breast Cancer (TNBC)

High Grade Serous Ovarian Cancer

Patients Requiring Veliparib Suspension Formulation

Interventions

Veliparib

Study Description

Brief Summary: This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to veliparib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria. EAP is also available for other indications where there is reasonable scientific basis for efficacy.

Detailed Description: Expanded Access